StockData

Genelux vs Senti Biosciences

GNLX and SNTI side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How GNLX and SNTI compare

Genelux is the larger company, worth 30 times as much as Senti Biosciences ($90.5M against $3.0M).

Genelux scores higher on the StockData Score (5 against 4 for Senti Biosciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricGNLXSNTI
Size and price
Market cap$90.5M$3.0M
Share price$2.00$0.097
Change, 1 year−62.4%−94.0%
Change, 5 years–−99.9%
Beta (5Y)0.733.17
StockData Score
Total score5 (better)4
Valuation score00
Growth score00
Performance score00
Health score5 (better)4
Dividend score00
Valuation
P/B5.6×–
FCF yield−31.7%–
Profitability
Return on equity−178% (better)−466%
Financial health
Debt / equity0.00–
Current ratio2.39 (better)0.83
Altman Z-score−14.83 (better)−21.38
Piotroski F-score12 (better)
Dividends and buybacks
Buyback yield−20.8%–
Shareholder yield−20.8%0.00% (better)
Ownership
Held by institutions21.7%18.6%
Held by insiders7.7%–
Insider net buying, 12 months−$341K–
Short interest, % of float10.9%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.